Investor Presentation

mRNA is a major new modality and market driver Leading COVID vaccine developers advancing non-COVID mRNA programs moderna +30 programs 20 non-COVID 2Pfizer $470M in mRNA vax 12.13.22 Moderna, Merck mRNA cancer vaccine slashes melanoma recurrence in Keytruda combo trial MERCK moderna R REPLIGEN BIONTECH 15 programs 15 non-COVID Growing number of large pharma companies with deep pipelines in mRNA CUREVAC 06.26.22 BioNTech/Roche mRNA Therapy for Pancreatic Cancer Inspires Early Optimism BIONTECH the RNA people® COVID program counts are from company presentations and websites December 2022 7 programs 4 non-COVID 04.20.22 Sanofi breaks ground on first-of-its-kind Evolutive Vaccine Facility in Asia sanofi 10

View entire presentation